{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:56:52Z","timestamp":1781776612000,"version":"3.54.5"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    The [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu-PSMA radioligand therapy is a\u00a0prostate-specific membrane antigen (PSMA) targeting treatment approved for patients with metastatic castration-resistant prostate cancer, after failure of androgen deprivation therapy or taxane-based chemotherapy. We report a\u00a0unique case of a\u00a0patient with metastatic hormone-sensitive prostate cancer (mHSPC) who received PSMA radioligand therapy as the sole treatment, without any prior or additional systemic treatment. Over a span of 8 years, the patient underwent 12\u00a0cycles of [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu-PSMA radioligand therapy, demonstrating favorable therapeutic response and a prolonged androgen deprivation therapy-free period. This case highlights the potential of long-term PSMA radioligand therapy as a\u00a0standalone option in selected mHSPC patients.\n                  <\/jats:p>","DOI":"10.1007\/s00508-025-02642-3","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:54:01Z","timestamp":1762426441000},"page":"376-379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["[177Lu]Lu-PSMA radioligand therapy as an initial approach in hormone-sensitive metastatic prostate cancer: a\u00a0case report"],"prefix":"10.1007","volume":"138","author":[{"given":"Ilva Kristiana","family":"Langrate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Kretschmer-Chott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schmitl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-6817","authenticated-orcid":false,"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sazan","family":"Rasul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"2642_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor\u00a0O, de Bono\u00a0J, Chi\u00a0KN, et\u00a0al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N\u00a0Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"11","key":"2642_CR2","doi-asserted-by":"publisher","first-page":"12244","DOI":"10.3390\/cimb46110727","volume":"46","author":"MA Kouri","year":"2024","unstructured":"Kouri\u00a0MA, Georgopoulos\u00a0A, Manios\u00a0GE, et\u00a0al. Preliminary study on lutetium-177 and gold nanoparticles: apoptosis and radiation enhancement in hepatic cancer cell line. CIMB. 2024;46(11):12244\u201359.","journal-title":"CIMB"},{"issue":"10","key":"2642_CR3","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad\u00a0AA, Bressel\u00a0M, Tan\u00a0TH, et\u00a0al. Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (upfrontPSMA): a\u00a0multicenter, open-label, randomised, phase\u00a02\u00a0study. Lancet Oncol. 2024;25(10):1267\u201376.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2642_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40487-020-00119-z","volume":"8","author":"K Ng","year":"2020","unstructured":"Ng\u00a0K, Smith\u00a0S, Shamash\u00a0J. Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting. Oncol Ther. 2020;8(2):209\u201330.","journal-title":"Oncol Ther"},{"issue":"10336","key":"2642_CR5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi\u00a0K, Foulon\u00a0S, Carles\u00a0J, et\u00a0al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a\u00a0multicentre, open-label, randomised, phase\u00a03\u00a0study with a\u00a02\u00a0\u00d7 2 factorial design. Lancet. 2022;399(10336):1695\u2013707.","journal-title":"Lancet"},{"key":"2642_CR6","doi-asserted-by":"publisher","first-page":"e433126","DOI":"10.1200\/EDBK_433126","volume":"44","author":"LM Gudenkauf","year":"2024","unstructured":"Gudenkauf\u00a0LM, Gray\u00a0S, Gonzalez\u00a0DB, et\u00a0al. Balancing hormone therapy: mitigating adverse effects of androgen-deprivation therapy and exploring alternatives in prostate cancer management. Am Soc Clin Oncol Educ Book. 2024;44:e433126.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"2642_CR7","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1007\/s00259-023-06165-9","volume":"50","author":"M Sathekge","year":"2023","unstructured":"Sathekge\u00a0M, Bruchertseifer\u00a0F, Vorster\u00a0M, Lawal\u00a0IO, Mokoala\u00a0K, Reed\u00a0J, et\u00a0al. 225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings. Eur J Nucl Med Mol Imaging. 2023;50(7):2210\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2642_CR8","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil\u00a0C, Fendler\u00a0WP, Eiber\u00a0M, et\u00a0al. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50(9):2830\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2642_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2967\/jnumed.123.265986","volume":"65","author":"L Steinhelfer","year":"2024","unstructured":"Steinhelfer\u00a0L, Lunger\u00a0L, Cala\u00a0L, et\u00a0al. Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy. J\u00a0Nucl Med. 2024;65(1):79\u201384.","journal-title":"J Nucl Med"},{"issue":"8","key":"2642_CR10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/14796694.2025.2468569","volume":"21","author":"\u00c1 Borque-Fernando","year":"2025","unstructured":"Borque-Fernando \u00c1, Alonso-Gordoa\u00a0T, Juan-Fita\u00a0MJ, Lopez Campos\u00a0F, P\u00e9rez-Fentes\u00a0DA, Vilaseca\u00a0A, et\u00a0al. Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC. Future Oncol. 2025;21(8):991\u20131003.","journal-title":"Future Oncol"},{"issue":"1","key":"2642_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00259-020-04797-9","volume":"48","author":"H Ahmadzadehfar","year":"2021","unstructured":"Ahmadzadehfar\u00a0H, Rahbar\u00a0K, Baum\u00a0RP, et\u00a0al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A\u00a0WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48(1):113\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl\u00a04","key":"2642_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00508-025-02544-4","volume":"137","author":"S Mirzaei","year":"2025","unstructured":"Mirzaei\u00a0S, Schweighofer-Zwink\u00a0G, Ofner\u00a0H, et\u00a0al. Use of 177Lu prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer. Wien Klin Wochenschr. 2025;137(Suppl\u00a04):157\u201366.","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"2642_CR13","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41598-023-29634-5","volume":"13","author":"Y Hakozaki","year":"2023","unstructured":"Hakozaki\u00a0Y, Yamada\u00a0Y, Takeshima\u00a0Y, et\u00a0al. Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients. Sci Rep. 2023;13(1):2672.","journal-title":"Sci Rep"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02642-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02642-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02642-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:39:01Z","timestamp":1781775541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02642-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":13,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2642"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02642-3","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I.K.\u00a0Langrate, E.\u00a0Kretschmer-Chott, S.\u00a0Schmitl, S.F.\u00a0Shariat, M.\u00a0Hacker, G.\u00a0Kramer and S.\u00a0Rasul declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All methods mentioned were in accordance with the ethical standards. Informed consent was obtained from the patient described in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}